Advertisement

MSVirtual2020: ACTRIMS-ECTRIMS Latest

Eculizumab reduces long-term relapse risk in AQP4+ NMOSD

Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...

Advertisement